Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 29, 2013

Auxilium Snaps Up Urolology Therapeutics Firm Actient in $585M Deal

  • Auxilium Pharmaceuticals is slated to acquire urology therapeutics firm Actient Holdings in a $585 million up-front cash deal. Through this acquisition, Auxilium also expects to receive a tax benefit with a net value of around $60 million, at present.

    The Malvern, PA-based pharma’s acquisition of Actient will expand its specialty therapeutic offerings. Actient’s urology portfolio includes Edex®, an injectable drug for erectile dysfunction, among other drug and medical device offerings. Actient has a staff of 165, including 100 sales reps.

    Adrian Adams, Auxilium president and CEO, called the deal "a compelling fit from both a strategic and financial standpoint” because, he said in a statement, “the transaction creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio as we pursue the potential expansion of our label for Xiaflex® in Peyronie's disease.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »